Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Amber Weller"'
Autor:
Orli S. Schwartz, Paul Amminger, Bernard T. Baune, Gillinder Bedi, Michael Berk, Sue M. Cotton, Rothanthi Daglas-Georgiou, Nick Glozier, Ben Harrison, Daniel F. Hermens, Emma Jennings, Jim Lagopoulos, Colleen Loo, Sumudu Mallawaarachchi, Donel Martin, Bethany Phelan, Nikki Read, Anthony Rodgers, Lianne Schmaal, Andrew A. Somogyi, Lily Thurston, Amber Weller, Christopher G. Davey
Publikováno v:
Trials, Vol 24, Iss 1, Pp 1-19 (2023)
Abstract Background Existing treatments for young people with severe depression have limited effectiveness. The aim of the Study of Ketamine for Youth Depression (SKY-D) trial is to determine whether a 4-week course of low-dose subcutaneous ketamine
Externí odkaz:
https://doaj.org/article/f7258bbfdb86416e8c9748aa41a5d93f
Autor:
Michael Berk, Mohammadreza Mohebbi, Olivia M. Dean, Sue M. Cotton, Andrew M. Chanen, Seetal Dodd, Aswin Ratheesh, G. Paul Amminger, Mark Phelan, Amber Weller, Andrew Mackinnon, Francesco Giorlando, Shelley Baird, Lisa Incerti, Rachel E. Brodie, Natalie O. Ferguson, Simon Rice, Miriam R. Schäfer, Edward Mullen, Sarah Hetrick, Melissa Kerr, Susy M. Harrigan, Amelia L. Quinn, Catherine Mazza, Patrick McGorry, Christopher G. Davey
Publikováno v:
BMC Medicine, Vol 18, Iss 1, Pp 1-12 (2020)
Abstract Background Inflammation contributes to the pathophysiology of major depressive disorder (MDD), and anti-inflammatory strategies might therefore have therapeutic potential. This trial aimed to determine whether adjunctive aspirin or rosuvasta
Externí odkaz:
https://doaj.org/article/e324650ad0254ef1909b710205791da0
Autor:
Eoin Killackey, Cathy Mihalopoulos, Maximus Berger, Andrea Baker, James Scott, Jessica Spark, Iain S. McGregor, Hok Pan Yuen, David Cotter, Melissa Kerr, Alison R. Yung, Andrew Thompson, Sally O'Callaghan, Scott R. Clark, Patrick D. McGorry, Amber Weller, Brian O'Donoghue, G. Paul Amminger, Barnaby Nelson, Charlotte Pugh, Ashleigh Lin, Zoltán Sarnyai
Publikováno v:
Early Intervention in Psychiatry. 16:419-432
Background No biological treatment has been firmly established for the at-risk stage of psychotic disorder. In this study we aim to test if subthreshold psychotic symptoms can be effectively treated with cannabidiol (CBD), a non-psychoactive compound
Autor:
Nikolai Albert, Iris E. C. Sommer, Wim Veling, Marieke J. H. Begemann, Eoin Killackey, Merete Nordentoft, Amber Weller, Kelly Allott, Helene Speyer
Publikováno v:
The Lancet. Psychiatry, 7(10), 841-842. ELSEVIER SCI LTD
Autor:
Edward Mullen, Christopher G. Davey, Sue M. Cotton, Aswin Ratheesh, Susy Harrigan, Mohammadreza Mohebbi, Sarah E Hetrick, Mark Phelan, Miriam R. Schäfer, G. Paul Amminger, Seetal Dodd, Natalie O. Ferguson, Shelley Baird, Rachel E. Brodie, Olivia M Dean, Andrew Mackinnon, Amber Weller, Patrick D. McGorry, Lisa Incerti, Melissa Kerr, Michael Berk, Amelia L. Quinn, Andrew M. Chanen, Francesco Giorlando, Simon M Rice, Catherine Mazza
Publikováno v:
BMC Medicine
BMC Medicine, Vol 18, Iss 1, Pp 1-12 (2020)
BMC Medicine, Vol 18, Iss 1, Pp 1-12 (2020)
Background Inflammation contributes to the pathophysiology of major depressive disorder (MDD), and anti-inflammatory strategies might therefore have therapeutic potential. This trial aimed to determine whether adjunctive aspirin or rosuvastatin, comp
Autor:
John Koutsogiannis, Mark Phelan, Günter Paul Amminger, Amelia L. Quinn, Melissa Kerr, Sarah E Hetrick, Nikolaos Kazantzis, Alexendra G Parker, Aswin Ratheesh, Edward Mullen, Sue M. Cotton, Christopher G. Davey, Patrick D. McGorry, Simon M Rice, Ben J. Harrison, Lisa Catania, Michael Berk, Olivia M Dean, Andrew M. Chanen, Amber Weller
Publikováno v:
The lancet. Psychiatry. 6(9)
Summary Background Medication is commonly used to treat youth depression, but whether medication should be added to cognitive behavioural therapy (CBT) as first-line treatment is unclear. We aimed to examine whether combined treatment with CBT and fl
Autor:
John Gleeson, Patrick D. McGorry, Carli Ellinghaus, G. Paul Amminger, Lex Wunderink, Stephen J. Wood, Kelly Allott, Susy Harrigan, Kristi van der El, Amber Weller, Eoin Killackey, Brian O'Donoghue, Peter Koval, Mario Alvarez-Jimenez, Jesse Gates, Sarah Bendall, Cali F. Bartholomeusz, Aswin Ratheesh, Marianne Mueller, Christos Pantelis, Andrea Polari, Jessica O'Connell, Alex Fornito, Barnaby Nelson
Antipsychotic medication has been the mainstay of treatment for psychotic illnesses for over 60 years. This has been associated with improvements in positive psychotic symptoms and a reduction in relapse rates. However, there has been little improvem
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4c656966569cd6bea03b3e338afad411
https://acuresearchbank.acu.edu.au/item/8wqyw/can-antipsychotic-dose-reduction-lead-to-better-functional-recovery-in-first-episode-psychosis-a-randomized-controlled-trial-of-antipsychotic-dose-reduction-the-reduce-trial-study-protocol
https://acuresearchbank.acu.edu.au/item/8wqyw/can-antipsychotic-dose-reduction-lead-to-better-functional-recovery-in-first-episode-psychosis-a-randomized-controlled-trial-of-antipsychotic-dose-reduction-the-reduce-trial-study-protocol